Auxora for the Treatment of AKI and Modulation of Injurious Crosstalk with the Lung: A Randomized Control Trial (KOURAGE)
Internal Medicine
Nephrology
Pulmonology
Endocrinology
Kidney Disease
Respiratory Distress Syndrome
Respiratory Failure
Kidney Failure
Diabetes
Adult Subjects
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.